MT020
/ Suzhou Maximum Bio-tech
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
August 08, 2024
T-MAXIMUM PHARMACEUTICAL Announces Latest Clinical Advances in Allogeneic CAR-T Cell Therapy Breakthrough for Solid Tumors
(PRNewswire)
- "...In addition to MT027, T-MAXIMUM is advancing two other allogeneic CAR-T cell therapy candidates: MT026 and MT020. MT026 targets IL13Rα2 and is being developed for the treatment of solid tumors....MT020 is being developed to treat B-cell related autoimmune diseases."
Pipeline update • Immunology • Solid Tumor
1 to 1
Of
1
Go to page
1